Title: Interferon Treatment in Patients with Hypereosinophilia
Volume: 12
Issue: 3
Author(s): Ole Weis Bjerrum
Affiliation:
Keywords:
Eosinophilia, interferon, treatment, classification, review, pure idiopathic hypereosinophilia, hypereosinophilia, cyclophosphamide
Abstract: Most of the primary conditions with eosinophilia have now been characterized by clonality in 2008 by the WHO classification, which thereby provide a basis for separation of patients who may benefit a targeted therapy, i.e. by tyrosine kinase inhibition - and who may not. Treatment with interferon-α was introduced some 20 years ago and still has a role in subsets of patients, which is evident from this review of casuistic reports of treatment. However, controlled, randomized, prospective, clinical trials in multi-center studies are needed to clarify dosages, monitoring, prognosis and perhaps combination therapies with interferon-α, i.e. antibodies or other immune suppressants, in the rare patients with primary eosinophilia,
